ArticleApplied biochemistry and biotechnology2026
Modulatory Role of Moringa Oleifera-Loaded Silver Nanoparticles on UCP1 and PPARGC1A Genes Expression in an Obesity Rat Model.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity remains a global health crisis, with limited therapeutic options for addressing metabolic dysfunction and inflammation. This study evaluates the therapeutic potential of Moringa Oleifera-loaded silver nanoparticles (MO-AgNPs) in modulating obesity-related biochemical and genetic markers. To optimize the synthesis of MO-AgNPs, Response Surface Methodology (RSM) using Design Expert software was employed to identify the optimal conditions for minimizing particle size, polydispersity index, and maximizing zeta potential. Male albino rats with high-carbohydrate, high-fat diet (HCHFD)-induced obesity were treated with AgNPs, Moringa Oleifera extract, or MO-AgNPs. Key assessments included biochemical markers, lipid profiles, adipokines, and the expression of thermogenic and metabolic genes (UCP1, PPARGC1A), along with histopathological evaluation of liver and pancreatic tissues. Transmission electron microscopy revealed spherical particles with an average size of approximately 40 nm, consistent with dynamic light scattering data. Treatment with MO-AgNPs significantly enhanced insulin sensitivity, improved lipid profiles, and regulated adipokine levels, while upregulating UCP1 and PPARGC1A expression more effectively than other treatments. Histological analysis demonstrated substantial restoration of liver and pancreatic tissue architecture, highlighting the protective effects of MO-AgNPs. Overall, MO-AgNPs represent an innovative therapeutic strategy, combining the bioactive properties of Moringa Oleifera with the enhanced functionality of silver nanoparticles, showing strong potential for addressing obesity and its associated metabolic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.